InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,048.42
(
-0.46%
)
US TECH 100
17,168.35
(
0.63%
)
Dow Jones
38,085.80
(
-0.98%
)
Brent Oil
88.15
(
-0.01%
)
Bitcoin
64,422.35
(
-0.10%
)
Post# of 20617
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Biotech Pharmer

Send PM Follow Ignore
Followers 0
Posts 1521
Boards Moderated 0
Alias Born 09/16/2005

Biotech Pharmer

Re: None

Saturday, 09/16/2017 10:06:27 PM

Saturday, September 16, 2017 10:06:27 PM

Post# of 20617
It's fairly obvious that INNV will be a one trick pony with Fluticare. All the vagiglide, wadstopper, and prostagorx sales in the world that generate $1 in revenue at a cost of $1.50 to do so can go on for only so long. FlutiCare is, and has been, the only thing that matters. Can Damaj bring it to market successfully with all of the negative assets in play that he's spun the company wheels on? He's got a 6-9 month window to bring it on with Fluticare. How will he pay to launch it in the midst of GSK's huge Flonase marketing machine?
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up